ABSTRACT BACKGROUND Although epinephrine is essential for successful return of spontaneous circulation (ROSC), the influence
I
nternational resuscitation guidelines recommend administering epinephrine every 3 to 5 min during cardiac arrest resuscitation regardless of the initial rhythm (1) . The alpha-adrenergic effects of epinephrine can increase coronary and cerebral perfusion pressure during the resuscitation period (2,3) and subsequently help achieve return of spontaneous circulation (ROSC). However, epinephrine may exert adverse effects during the postresuscitation phase and contribute to myocardial dysfunction, increased oxygen requirements, and microcirculatory abnormalities (4) (5) (6) (7) (8) .
Although epinephrine can increase the likelihood of achieving ROSC, the balance of the effects of epinephrine on long-term survival remains uncertain.
A randomized study found no overall survival effect of medication treatments that included epinephrine (9) . In a large observational study, epinephrine was associated with a lower likelihood of long-term survival (10) . In each of these studies, epinephrine was associated with a greater likelihood of ROSC, but the early potential benefit did not translate into a greater likelihood of long-term survival because outcomes among the epinephrine-treated patients were worse during the post-resuscitation phase.
We sought to better understand the potential adverse effects of epinephrine when used during the postresuscitation phase. We evaluated the relationship between use of epinephrine during resuscitation and survival among a cohort of patients resuscitated from out-of-hospital cardiac arrest (OHCA) and admitted to the hospital with ROSC. We also evaluated whe- Post-resuscitation shock was defined as the occurrence or persistence of arterial hypotension (mean arterial pressure <60 mm Hg or systolic blood pressure <90 mm Hg) sustained for more than 6 h after ROSC despite adequate fluid resuscitation and continuous vasopressor infusion (13 Epinephrine and Hospital Prognosis After OHCA outcome. The propensity of receiving epinephrine was determined using pre-treatment characteristics. In an effort to control for confounding, we also used different methods (14, 15) that included a logistic regression model adjusted for the propensity score, 2 conditional logistic regression analyses after matching on the propensity score in a 1:1 manner, stratification on quintiles of propensity score, and an inverse probability of treatment weighted logistic regression model. Here, we performed an additional analysis based on 1,000 bootstrap samples drawn with replacement from the study population. At this step, all models were adjusted on hospital potential confounders: PCI, therapeutic hypothermia, blood lactate level, and occurrence of post-cardiac arrest shock.
We assessed for differences in the epinephrineoutcome association among subgroups by including an interaction (cross-product) term between the use of epinephrine and the covariate of interest (initial rhythm, intervals, post-cardiac arrest shock, etiology, coronary angiography, and therapeutic hypothermia).
Because the period of study was more than a decade, we performed an ancillary analysis on the period of inclusion, especially before and after 2005, the year of removed and new guidelines concerning pre-hospital care (16). Finally, an ancillary analysis was performed focusing on the intervals between cardiac arrest and ACLS (first administration of epinephrine).
All tests were 2-sided. A p value #0.05 was considered statistically significant. All analyses were performed using Stata 11.2/SE software (College Station, Texas).
RESULTS
During the study period, 1,646 patients achieved ROSC and were admitted to the hospital. Of these, 90 (5.5%) had missing epinephrine status and were excluded from the analysis. Abbreviations as in Table 1 . IPTW ¼ inverse probability of treatment weighting; PS ¼ propensity score; SMR ¼ standard mortality ratio.
Dumas et al. Table 1 ).
The logistic model used to estimate the propensity score for receiving epinephrine using all available covariates yielded a C statistic of 0.80. Moreover, the delay between cardiac arrest and first dose of epinephrine was linearly related to a bad outcome. Patients in whom epinephrine was given within the first 9 min after cardiac arrest had a better 0.14 to 0.37) for >5 mg (Figure 3) . A similar dose relationship was observed across the a priori subgroups (Online Figures 3A to 3C ). It could be contended that epinephrine should be considered a surrogate marker of severity rather than an independent predictive factor, complicating the current debate on the benefit of this agent (26) . However, this relationship has been already described when looking at observational data and the few randomized studies that were recently performed (5, 27) .
We made multiple methodological efforts (using propensity score, cross-matching, and different sensitivity analysis) to discriminate the specific role of the intervention. The results were robust regardless of the methodological approach. To our knowledge, this is the first study depicting such a linear relationship between the dose and outcome, which is consistent with an increasing effect of the ascendant dose of the drug. Some studies have previously shown that repeated and increased doses of epinephrine could worsen the chances of survival (28, 29) .
Before incriminating the drug itself, our findings probably should provoke further discussion on the most appropriate scheme of treatment and its interaction regarding the resuscitation phases. Our sensitivity analyses showed that the role of epinephrine did not change according to ACLS delay or length of resuscitation but was clearly dependent on the timing of first administration. These last findings are consistent with other studies, emphasizing the potential benefit of an early dose of epinephrine (30) (31) (32) .
Moreover, these observations concur with what
Weisfeldt and Becker (33) previously described as the 3 phases of resuscitation in VF arrest: "the electrical phase" within the first few minutes after arrest, in which epinephrine should not be required; "the circulatory phase," during which time chest compressions and epinephrine could help reperfusion; and finally "the metabolic phase," when the drug may be detrimental in regard to the peripheral ischemia release of massively cytotoxic proteins. As supported by our results, it is highly probable that patients receiving late or repeated doses of epinephrine have little or low chance of survival. Currently, no existing alternative can bring these patients back from neardeath except mechanical circulatory assistance in very select cases. Altogether, the scheme and timing of administration may be crucial to provide the appropriate effect of epinephrine.
This study highlights the need to assess the quality of resuscitation, such as the quality of CPR and ACLS response (34) (35) (36) , to improve clinical practice (37, 38) . Administration of epinephrine during cardiac arrest is associated with worse neurological outcomes in resuscitated patients. This effect is consistent in all subgroups of patients and increased with the cumulated dosage and delay of the first administration (association between epinephrine and worse neurological outcome at discharge, expressed as odds ratios with 95% confidence intervals, adjusted on confounders).
information ascertained using a standard approach to data abstraction regarding care and outcome.
CONCLUSIONS
In this large cohort of patients who achieved ROSC after OHCA, we observed an adverse association between epinephrine and neurologically intact survival despite rigorous efforts to address confounding; this Epinephrine and Hospital Prognosis After OHCA D E C E M B E R 9 , 2 0 1 4 : 2 3 6 0 -7
